

DAFTAR PUSTAKA

- Acen, E. L., Kateete, D. P., Worodria, W., Olum, R., Joloba, M. L., Bbuye, M., & Biraro, I. A. (2022). Evaluation of circulating serum *Cathelicidin LL-37* levels as a potential biomarker to discriminate between active and latent tuberculosis in Uganda. *PLoS ONE*, 17(8 August).
<https://doi.org/10.1371/journal.pone.0272788>
- Al-Jaberi, F. A. H., Crone, C. G., Lindenstrøm, T., Arildsen, N. S., Lindeløv, E. S., Aagaard, L., Gravesen, E., Mortensen, R., Andersen, A. B., Olgaard, K., Hjaltelin, J. X., Brunak, S., Bonefeld, C. M., Kongsbak-Wismann, M., & Geisler, C. (2022). Reduced vitamin D-induced *Cathelicidin LL-37* production and killing of *Mycobacterium tuberculosis* in macrophages from a patient with a non-functional vitamin D receptor: A case report. *Frontiers in Immunology*, 13. <https://doi.org/10.3389/fimmu.2022.1038960>
- Alrehaili, J. (2023a). Leprosy Classification, Clinical Features, Epidemiology, and Host Immunological Responses: Failure of Eradication in 2023. *Cureus*.
<https://doi.org/10.7759/cureus.44767>
- Alrehaili, J. (2023b). Leprosy Classification, Clinical Features, Epidemiology, and Host Immunological Responses: Failure of Eradication in 2023. *Cureus*.
<https://doi.org/10.7759/cureus.44767>
- Antunes, D. E., Maria, I., Goulart, B., Ingrid, M., Lima, S., Alves, P. T., Cristina, P., Tavares, B., & Goulart, L. R. (2019). *Research Article Differential Expression of IFN-γ*.
- Argentina, F., Suwarsa, O., Gunawan, H., & Berbudi, A. (2023a). A Comparison of *Cathelicidin LL-37* Levels in the Skin of Leprosy Patients and Their Household Contacts. *Acta Medica Academica*, 52(3), 195–200.
<https://doi.org/10.5644/ama2006-124.424>
- Argentina, F., Suwarsa, O., Gunawan, H., & Berbudi, A. (2023b). Gene Expression of Human Beta-Defensin-3 and *Cathelicidin LL-37* in the Skin of Leprosy Patients, Household Contacts, and Healthy Individuals from Indonesia. *Clinical, Cosmetic and Investigational Dermatology*, 16, 1485–1492.
<https://doi.org/10.2147/CCID.S405932>
- Arunagiri, K., Sangeetha, G., Sugashini, P. K., Balaraman, S., & Showkath Ali, M. K. (2017). Nasal PCR assay for the detection of *Mycobacterium leprae* pra gene to study subclinical infection in a community. *Microbial Pathogenesis*, 104, 336–339. <https://doi.org/10.1016/j.micpath.2017.01.046>
- Beissner, M., Woestemeier, A., Saar, M., Badziklou, K., Maman, I., Amedifou, C., Wagner, M., Wiedemann, F. X., Amekuse, K., Kobara, B., Herbing, K. H., Kere, A. B., Löscher, T., & Bretzel, G. (2019). Development of a combined RLEP/16S rRNA (RT) qPCR assay for the detection of viable *M. leprae* from nasal swab samples. *BMC Infectious Diseases*, 19(1).

<https://doi.org/10.1186/s12879-019-4349-9>

Bhandari, J., Awais, M., Robbins, B., & et al. (2021). *Leprosy*. StatPearls Publishing LLC.

Cambri, G., & Mira, M. T. (2018). Genetic susceptibility to leprosy-from classic immune-related candidate genes to hypothesis-free, whole genome approaches. In *Frontiers in Immunology* (Vol. 9, Issue JUL). Frontiers Media S.A. <https://doi.org/10.3389/fimmu.2018.01674>

Gilmore, A., Roller, J., & Dyer, J. A. (n.d.). *SCIENCE OF MEDICINE | FEATURE SERIES Leprosy (Hansen's disease): An Update and Review*.

Grossi de Oliveira AL, Chaves AT, Cardoso MS, Pinheiro GRG, Antunes DE, Grossi MA de F, et al. Reduced vitamin D receptor (VDR) and cathelicidin antimicrobial peptide (CAMP) gene expression contribute to the maintenance of inflammatory immune response in leprosy patients. *Microbes and Infection*. 2022 Sep 1;24(6–7).

Hacker, M. A., Sales, A. M., Duppre, N. C., Sarno, E. N., & Moraes, M. O. (2021). Leprosy incidence and risk estimates in a 33-year contact cohort of leprosy patients. *Scientific Reports*, 11(1). <https://doi.org/10.1038/s41598-021-81643-4>

Hostiadi, M., Rusyati, L. M. M., Puspawati, N. M. D., Indira, I. G. A. A. E., Darmaputra, I. G. N., & Karna, N. L. P. R. V. (2023). Kadar Cathelicidin rendah berkorelasi negatif terhadap indeks bakteri pasien Morbus Hansen Tipe Multibasiler. *Intisari Sains Medis*, 14(3), 1372–1378. <https://doi.org/10.15562/ism.v14i3.1804>

Khariri, K., Sunarno, S., Panjaitan, N. S. D., Yuliandari, P., Handayani, S., Dewi, R. M., Sari, N. I. P., Fitriana, F., Pasiana, A. D., Kusri, I., & Njoto, E. N. (2026). Determinants of subclinical leprosy among household contacts in Indonesia: serological and socio-demographic factors. *PeerJ*, 14, e20631. <https://doi.org/10.7717/peerj.20631>

Krawiec, P., & Pac-Kożuchowska, E. (2021). *Cathelicidin LL-37 – a novel potential marker of pediatric inflammatory bowel disease*. *Journal of Inflammation Research*, 14, 163–174. <https://doi.org/10.2147/JIR.S288742>

Lemieszek, M. K., Golec, M., Zwoliński, J., Dutkiewicz, J., & Milanowski, J. (2022). *Cathelicidin LL-37 influence on pathological activation of Wnt pathway in murine model of hypersensitivity pneumonitis*. *Annals of Agricultural and Environmental Medicine*, 29(3), 358–364. <https://doi.org/10.26444/aaem/153082>

Marques, L. É. C., Frota, C. C., Quetz, J. da S., Bindá, A. H., Mota, R. M. S., Pontes, M. A. de A., Gonçalves, H. de S., Kendall, C., & Kerr, L. R. F. S. (2018). Evaluation of 16S rRNA qPCR for detection of *Mycobacterium leprae*

- DNA in nasal secretion and skin biopsy samples from multibacillary and paucibacillary leprosy cases. *Pathogens and Global Health*, 112(2), 72–78.
<https://doi.org/10.1080/20477724.2017.1415736>
- Matzner, M., al Samie, A. R., Winkler, H. M., Nemeth, J., Grasnek, A., Indra, A., Bieglmayer, C., & Winkler, S. (2011). Low serum levels of cathelicidin LL-37 in leprosy. *Acta Tropica*, 117(1), 56–59.
<https://doi.org/10.1016/j.actatropica.2010.09.007>
- Mi, Z., Liu, H., & Zhang, F. (2020). Advances in the Immunology and Genetics of Leprosy. In *Frontiers in Immunology* (Vol. 11). Frontiers Media S.A.
<https://doi.org/10.3389/fimmu.2020.00567>
- Mi, Z., Liu, H., & Zhang, F. (2024). Advances in the pathogenic, genetic and immunological studies of leprosy. In *hLife* (Vol. 2, Issue 1, pp. 6–17). Elsevier B.V. <https://doi.org/10.1016/j.hlife.2023.10.003>
- Mostafa, H. M. A., Soliman, N. A., Far, N. N. El, & Nassar, S. O. (2023). A current perspective on leprosy (Hansen's disease). *International Journal of Dermatology, Venereology and Leprosy Sciences*, 6(2), 130–136.
<https://doi.org/10.33545/26649411.2023.v6.i2b.161>
- Nath Former Senior Professor, I. (2016). IMMUNOPATHOGENESIS OF LEPROSY: A MODEL FOR T CELL ANERGY. In *Citation: EMJ Dermatol.*
- Noer, A., Pertiwi, A. M., & Syahrul, F. (2024). Risk Factors For Leprosy: A Systematic Review. *The Indonesian Journal of Public Health*, 19(3), 575–589.
<https://doi.org/10.20473/ijph.v19i3.2023.575-589>
- Nogueira, K. R. C., de Almeida Freitas, H., da Paz, M. N. V. T., Costa, A. R. R. S., Nunes, I. C., de Araújo Souza, J. L. R., de Oliveira Barreto, E., de Souza Ferro, J. N., de Carvalho Fraga, C. A., do Carmo, R. F., Silva, A. T. P., & de Sales Marques, C. (2025). Association between MBL2 gene polymorphism and protection against leprosy in a population of northeastern brazil: a case-control study. *Scientific Reports*, 15(1).
<https://doi.org/10.1038/s41598-025-11597-4>
- Price, V. G. (2017). Factors preventing early case detection for women affected by leprosy: a review of the literature. *Global Health Action*, 10(sup2).
<https://doi.org/10.1080/16549716.2017.1360550>
- Quilter, E. E. V., Lockwood, D. N. J., & Butlin, C. R. (2022). Rising percentage of new female leprosy cases since 2004. *Leprosy Review*, 93(4), 364–369.
<https://doi.org/10.47276/lr.93.4.364>
- Reinholz, M., Ruzicka, T., & Schaubert, J. (2012). Cathelicidin LL-37 LL-37: An antimicrobial peptide with a role in inflammatory skin disease. In *Annals of Dermatology* (Vol. 24, Issue 2, pp. 126–135).
<https://doi.org/10.5021/ad.2012.24.2.126>

- Silva, M. J. A., Silva, C. S., Brasil, T. P., Alves, A. K., dos Santos, E. C., Frota, C. C., Lima, K. V. B., & Lima, L. N. G. C. (2024). An update on leprosy immunopathogenesis: systematic review. In *Frontiers in Immunology* (Vol. 15). Frontiers Media SA. <https://doi.org/10.3389/fimmu.2024.1416177>
- Tamara, R., Muchtar, S. V., Amin, S., Seweng, A., Sjahril, R., & Adam, A. M. (2018). Serum Iron, Total Iron Binding Capacity and Transferrin Saturation Levels in Leprosy Patients before Multi Drug Therapy - *World Health Organization* (MDT-WHO) Compared with Healthy Control Group. *International Journal of Medical Reviews and Case Reports*, 2(4), 105–108.
- Voronko, O. E., Khotina, V. A., Kashirskikh, D. A., Lee, A. A., & Gasanov, V. A. oglu. (2025). Antimicrobial Peptides of the *Cathelicidin LL-37* Family: Focus on LL-37 and Its Modifications. In *International Journal of Molecular Sciences* (Vol. 26, Issue 16). Multidisciplinary Digital Publishing Institute (MDPI). <https://doi.org/10.3390/ijms26168103>
- Wang, Y., Xiao, D., Wu, M., Qing, L., Yang, T., Xiao, P., & Deng, D. (2023). Epidemiological Characteristics and Factors Associated with Cure of Leprosy in Chongqing, China, from 1949 to 2019. *American Journal of Tropical Medicine and Hygiene*, 108(1), 165–173. <https://doi.org/10.4269/ajtmh.22-0474>

LAMPIRAN

Lampiran 1. Etik Penelitian



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.



Contact Person: dr. Agussalim Bukhari, MMed, PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor: 1011/UN4.6.4.5.31/ PP36/ 2025

Tanggal: 25 Nopember 2025

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH25100857	No Sponsor	
Peneliti Utama	dr. Nur Hasira Mustakim	Sponsor	
Judul Peneliti	Analisis Perbandingan Kadar Cathelicidin LL-37 Pasien Kusta Dan Kontak Serumah Di Kepulauan Bonerate Selayar		
No Versi Protokol	1	Tanggal Versi	14 Oktober 2025
No Versi PSP	1	Tanggal Versi	14 Oktober 2025
Tempat Penelitian	RS Universitas Hasanuddin Makassar dan Kepulauan Bonerate, Kabupaten Selayar		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku 25 Nopember 2025 sampai 25 Nopember 2026	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Prof. dr. Muh Nasrum Massi, PhD, SpMK, Subsp. Bakt(K)	Tanda tangan 	
Sekretaris KEP Universitas Hasanuddin	Prof.dr. Firdaus Hamid, PhD, SpMK(K)	Tanda tangan 	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 2. Dokumentasi Penelitian

1. Anamnesis dan pemeriksaan fisik pasien



2. Pengambilan sampel darah



3. Penelitian di HUMRC



